China Cycle Releases 2025 International Bicycle Exhibition Analysis Report
In 2025, against the background of the tortuous global economic recovery, the CHINA CYCLE continued to show a steady growth trend, with the number of Chinese and foreign visitors and the number of exhibitors growing in both directions. The following is the basic situation of this exhibition:
1. Exhibition Scale
The total exhibition area of CHINA CYCLE 2025 is 160,000㎡. There are 13 exhibition halls and outdoor test ride and activity areas.
2. Participating Countries and Regions
1,582 exhibitors participated in CHINA CYCLE 2025 with 7,870 booths, including many leading enterprises in the two wheel industry. Among them are 118 overseas exhibitors with 670 booth from 25 countries and regions. The participation of international brands in the CHINA CYCLE not only reflects the increasing global visibility of the CHINA CYCLE, but also brings new opportunities and challenges to China's two-wheel industry.
3. Visitor Data
Buyers and visitors to the exhibition came from 144 countries and regions including mainland China, Taiwan, Hong Kong and Macao. The total number of visitor is 156,350 (including 139,818 Chinese visitors and 16,532 overseas visitors), the total number of entrance is 208,926 person times.
The annual CHINA CYCLE is a weathervane for the development of global bicycles and a grand events for bicycle companies. It will point out the direction for the future development of China's bicycle industry. In just four days, we have too many good memories and in-depth thinking. In the face of the increasing uncertainty in today's world, the CHINA CYCLE has established confidence for the entire industry!
We are looking forward to meeting you again in CHINA CYCLE 2026!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," stock code: a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ("Joincare Group"). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China region. Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii Bio has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events plus tiered royalties on net product sales. BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). Discovered through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. In phase 1 studies, BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: "The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare Group's proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections." Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, "The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs. We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options." About BRII-693 BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit About Joincare Group Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development. Forward-looking Statements This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. View original content to download multimedia: SOURCE Brii Biosciences Limited
Yahoo
an hour ago
- Yahoo
Asian Fund Pivots to Samsung Bet After Riding Pop Mart Rally
(Bloomberg) -- A peer-beating Asian equity fund is turning its sights on Samsung Electronics Co. after adding Pop Mart International Group Ltd. before the latter's share price surge. NYC Commutes Resume After Midtown Bus Terminal Crash Chaos Struggling Downtowns Are Looking to Lure New Crowds Massachusetts to Follow NYC in Making Landlords Pay Broker Fees Foreign Buyers Swoop on Cape Town Homes, Pricing Out Locals What Gothenburg Got Out of Congestion Pricing The $1.6 billion Ninety One Global Strategy Fund - Asian Equity Fund bought Pop Mart shares in March 2024 after its quantitative model identified the Labubu maker's earnings potential amid China's economic malaise, said London-based co-manager Charlie Linton. He recently turned overweight on Samsung, saying many investors have 'mispriced' the company because it's lagging rivals like SK Hynix Inc. in the high-bandwidth memory chip market. The fund's screening often highlights stocks that are 'discarded' by investors making decisions based on geographic and sector-driven trends, he said. It has returned 15% this year, outperforming 94% of peers, according to data compiled by Bloomberg. Linton's team relies on a model that screens stocks in the region using a blend of factors — quality, value, operational performance and technical momentum — and picks shares that are expected to withstand market volatility, he said. The fund viewed Pop Mart as undervalued given the popularity of its characters and intellectual property products. Its shares have soared roughly 600% over the past year. While Samsung's shares have trailed those of SK Hynix, which supplies HBM to Nvidia Corp, the firm's next-generation DRAM chip could help the stock catch up with peers once production takes off, Linton said. Samsung shares are up 20% this year, while SK Hynix's have jumped 60%. 'Currently everyone is underweight' Samsung, said Linton, who also owns SK Hynix shares. 'We've taken a bit more positive view, partly because the valuation looks very attractive.' Chinese equities make up almost a third of the fund. Linton owns shares of Naura Technology Group Co., which he sees as a proxy to China's rising semiconductor prowess thanks to its localization efforts and growth that's outpaced domestic counterparts. SNAP Cuts in Big Tax Bill Will Hit a Lot of Trump Voters Too America's Top Consumer-Sentiment Economist Is Worried How to Steal a House China's Homegrown Jewelry Superstar Sperm Freezing Is a New Hot Market for Startups ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
CORRECTING and REPLACING Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification
SEATTLE--(BUSINESS WIRE)--Please replace the release dated June 10, 2025 with the following corrected version due to multiple revisions. The updated release reads: Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification Integration Empowers Hospitals to Streamline Patient Onboarding, Enhance Compliance, and Improve Care Delivery with Seamless AI-Driven Identity Verification in Epic Vouched, the AI-powered identity verification platform trusted by leading healthcare systems, is now officially developing integration within Epic Toolbox Under Construction — bringing faster, safer patient onboarding, MyChart account creation and account recovery directly into Epic. This milestone enables hospitals and healthcare systems to seamlessly integrate VouchedRx, a customized identity verification solution for healthcare providers, powerful identity verification technology directly into their Epic electronic health record (EHR) systems—enhancing patient intake, compliance, and operational efficiency. As a trusted partner in healthcare, Vouched's AI-based platform automates and streamlines identity verification, reducing manual steps and administrative burdens. With its inclusion in Epic Toolbox Under Construction, healthcare providers will soon be able to slash patient intake times, minimize fraud risk, and speed access to care — while meeting the highest security and compliance standards. 'Being part of Epic Toolbox Under Construction is a strategic milestone in our mission to become an indispensable technology partner to hospitals and healthcare systems,' said Peter Horadan, CEO of Vouched. 'Our inclusion allows us to support healthcare organizations in modernizing how they verify patient identities—an essential step in reducing fraud, improving patient outcomes, and driving down costs.' Epic Toolbox Under Construction highlights products in specific categories that will become available once development is released by Epic and participating developers. The designation also signifies that the product adheres to Epic's recommended connection practices for a category, making it easier for health systems to adopt cutting-edge technologies without lengthy custom development cycles. By joining this ecosystem, Vouched furthers our commitment to empowering healthcare organizations to implement best-in-class ID verification natively within their clinical workflows. As digital transformation in healthcare accelerates, identity verification remains a critical first step in ensuring patient data integrity and delivering equitable, efficient care. With Vouched now part of Epic Toolbox Under Construction, providers will soon gain access to a seamless and scalable solution for verifying identities across diverse patient populations, including telehealth, urgent care, and in-person settings. Epic and MyChart are registered trademarks of Epic Systems Corporation. About Vouched Vouched is a leading AI-powered identity verification platform serving industries with high-stakes verification needs like healthcare, finance, and automotive. Trusted by enterprises around the world, Vouched verifies millions of identities annually with speed, accuracy, and compliance. To learn more, visit
